Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1954 1
1958 2
1959 1
1962 2
1965 1
1966 1
1967 3
1968 4
1969 2
1970 5
1971 4
1972 8
1973 9
1974 14
1975 6
1976 10
1977 11
1978 17
1979 20
1980 24
1981 28
1982 31
1983 31
1984 45
1985 60
1986 51
1987 56
1988 62
1989 53
1990 56
1991 52
1992 67
1993 49
1994 47
1995 43
1996 43
1997 37
1998 31
1999 47
2000 51
2001 52
2002 63
2003 46
2004 28
2005 45
2006 41
2007 58
2008 56
2009 56
2010 62
2011 51
2012 52
2013 55
2014 49
2015 42
2016 54
2017 48
2018 61
2019 45
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

1,958 results
Results by year
Filters applied: . Clear all
Page 1
[Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonamide structure].
Atheymen R, Affes H, Ksouda K, Mnif L, Sahnoun Z, Tahri N, Zeghal KM, Hammami S. Atheymen R, et al. Therapie. 2013 Nov-Dec;68(6):369-73. doi: 10.2515/therapie/2013064. Epub 2013 Dec 20. Therapie. 2013. PMID: 24356188 French.
Sulfasalazine is widely used in the treatment of chronic inflammatory bowel disease (IBD) and certain rheumatic diseases. However, its use is associated with a high rate of adverse effects (AEs) which can be cutaneous, hematological, renal, hepatic, gastroint
Sulfasalazine is widely used in the treatment of chronic inflammatory bowel disease (IBD) and certain rheumatic diseases. However, it
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
Schröder H, Evans DA. Schröder H, et al. Gut. 1972 Apr;13(4):278-84. doi: 10.1136/gut.13.4.278. Gut. 1972. PMID: 4402420 Free PMC article.
There was no correlation between the serum concentrations of sulphasalazine and the adverse effects. The slow acetylators obtained enhancement of serum concentrations of sulphapyridine earlier than the rapid acetylators. They also reported adverse e
There was no correlation between the serum concentrations of sulphasalazine and the adverse effects. The slow acetylato …
Sulfasalazine: a review of its use in the management of rheumatoid arthritis.
Plosker GL, Croom KF. Plosker GL, et al. Drugs. 2005;65(13):1825-49. doi: 10.2165/00003495-200565130-00008. Drugs. 2005. PMID: 16114981 Review.
Sulfasalazine was associated with broadly similar efficacy to that of various other DMARDs in several randomised, double-blind, comparative trials. ...Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effec
Sulfasalazine was associated with broadly similar efficacy to that of various other DMARDs in several randomised, double-blind, compa
Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis.
Williams HJ. Williams HJ. J Rheumatol Suppl. 1988 Sep;16:9-13. J Rheumatol Suppl. 1988. PMID: 2903928 Review.
Studies comparing sulfasalazine to gold or placebo are few in number. Two controlled trials have been conducted comparing sulfasalazine and placebo, and 2 uncontrolled trials have compared sulfasalazine and gold sodium thiomalate. ...These studies suggest tha …
Studies comparing sulfasalazine to gold or placebo are few in number. Two controlled trials have been conducted comparing sulfasal
[Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
Mundo A, Pedone V, Lamanna G, Cervini C. Mundo A, et al. Clin Ter. 1997 Jan-Feb;148(1-2):7-13. Clin Ter. 1997. PMID: 9377840 Review. Italian.
Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (2 g/die) and duration of therapy in 102 patients with RA. Adverse events occurred in 25.4% of all patients. In all patients the react
Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
Peppercorn MA. Peppercorn MA. Ann Intern Med. 1984 Sep;101(3):377-86. doi: 10.7326/0003-4819-101-3-377. Ann Intern Med. 1984. PMID: 6147110 Review.
The drug's mechanism of action may relate to its effects on prostaglandin synthesis or interference with arachidonic acid metabolism by the lipoxygenase pathway. Common adverse reactions of sulfasalazine, including nausea, headache, and anorexia, as well as h …
The drug's mechanism of action may relate to its effects on prostaglandin synthesis or interference with arachidonic acid metabolism …
Adverse effects of sulphasalazine.
Pullar T. Pullar T. Adverse Drug React Toxicol Rev. 1992 Summer;11(2):93-109. Adverse Drug React Toxicol Rev. 1992. PMID: 1353378 Review. No abstract available.
Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.
Svartz N. Svartz N. Am J Gastroenterol. 1988 May;83(5):497-503. Am J Gastroenterol. 1988. PMID: 2896459
Serious adverse effects are remarkably rare. Salazopyrin provoked an improvement in 75-80% of cases of UC. It is excellently adapted for long-term treatment and, in this respect, is clearly superior to corticosteroids. ...Adverse effects occur in about …
Serious adverse effects are remarkably rare. Salazopyrin provoked an improvement in 75-80% of cases of UC. It is excellently a …
Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis.
Skosey JL. Skosey JL. J Rheumatol Suppl. 1988 Sep;16:5-8. J Rheumatol Suppl. 1988. PMID: 2903927 Clinical Trial.
Sulfasalazine (0, 0.5, 1, or 2 g daily in divided doses) was given to patients with definite or classical rheumatoid arthritis (RA) insufficiently controlled by a nonsteroidal antiinflammatory drug. ...Although its use is limited by adverse reactions, sulfasalazi
Sulfasalazine (0, 0.5, 1, or 2 g daily in divided doses) was given to patients with definite or classical rheumatoid arthritis (RA) i
1,958 results
Jump to page
Feedback